1. Home
  2. CAPR vs BRBS Comparison

CAPR vs BRBS Comparison

Compare CAPR & BRBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • BRBS
  • Stock Information
  • Founded
  • CAPR 2005
  • BRBS 1893
  • Country
  • CAPR United States
  • BRBS United States
  • Employees
  • CAPR N/A
  • BRBS N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • BRBS Commercial Banks
  • Sector
  • CAPR Health Care
  • BRBS Finance
  • Exchange
  • CAPR Nasdaq
  • BRBS Nasdaq
  • Market Cap
  • CAPR 324.6M
  • BRBS 326.4M
  • IPO Year
  • CAPR N/A
  • BRBS N/A
  • Fundamental
  • Price
  • CAPR $6.28
  • BRBS $4.02
  • Analyst Decision
  • CAPR Strong Buy
  • BRBS
  • Analyst Count
  • CAPR 8
  • BRBS 0
  • Target Price
  • CAPR $24.75
  • BRBS N/A
  • AVG Volume (30 Days)
  • CAPR 1.4M
  • BRBS 444.7K
  • Earning Date
  • CAPR 08-11-2025
  • BRBS 10-28-2025
  • Dividend Yield
  • CAPR N/A
  • BRBS N/A
  • EPS Growth
  • CAPR N/A
  • BRBS N/A
  • EPS
  • CAPR N/A
  • BRBS N/A
  • Revenue
  • CAPR $13,392,150.00
  • BRBS $96,787,000.00
  • Revenue This Year
  • CAPR N/A
  • BRBS N/A
  • Revenue Next Year
  • CAPR $6,061.53
  • BRBS N/A
  • P/E Ratio
  • CAPR N/A
  • BRBS N/A
  • Revenue Growth
  • CAPR N/A
  • BRBS 10.13
  • 52 Week Low
  • CAPR $3.98
  • BRBS $2.66
  • 52 Week High
  • CAPR $23.40
  • BRBS $4.14
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 36.33
  • BRBS 63.43
  • Support Level
  • CAPR $6.17
  • BRBS $3.63
  • Resistance Level
  • CAPR $7.30
  • BRBS $4.14
  • Average True Range (ATR)
  • CAPR 0.43
  • BRBS 0.12
  • MACD
  • CAPR -0.11
  • BRBS 0.03
  • Stochastic Oscillator
  • CAPR 4.53
  • BRBS 75.49

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About BRBS Blue Ridge Bankshares Inc.

Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.

Share on Social Networks: